Are you trying to say that because Vascepa has now got a much larger larger expanded label with more indications that means that more people will stop taking the drug? What is your point?
Yes, as the percentage of new prescriptions increases away from a hard core base, I’d expect the refill percentage to drop some. How much? Dunno. But probably to more than 50% discontinuation after 1 year.
Market Data 
Markets 
AI
